Investigational cytokine-targeted therapies for ulcerative colitis

Bibliography

• Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol 2010;28:573-621
   PubMed Web of Science ®Google Scholar
• Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000;47(3):404-9
   PubMed Web of Science ®Google Scholar
• Travis SP, Stange EF, Lémann M, et al. European evidence-based Consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008;2(1):24-62
   PubMed Web of Science ®Google Scholar
• Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334(26):1717-25
   PubMed Web of Science ®Google Scholar
• Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385(6618):729-33
   PubMed Web of Science ®Google Scholar
• MacEwan DJ. TNF ligands and receptors–a matter of life and death. Br J Pharmacol 2002;135(4):855-75
   PubMed Web of Science ®Google Scholar
• Efimov GA, Kruglov AA, Tillib SV, et al. Tumor Necrosis Factor and the consequences of its ablation in vivo. Mol Immunol 2009;47(1):19-27
   PubMed Web of Science ®Google Scholar
• Wang F, Graham WV, Wang Y, et al. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol 2005;166(2):409-19
   PubMed Web of Science ®Google Scholar
• Pender SL, Fell JM, Chamow SM, et al. A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol 1998;160(8):4098-103
   PubMed Web of Science ®Google Scholar
• MacDonald TT, Hutchings P, Choy MY, et al. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990;81(2):301-5
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Gionchetti P, Ainsworth M, et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol 1999;94(10):2923-8
   PubMed Web of Science ®Google Scholar
• Neurath MF, Fuss I, Pasparakis M, et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 1997;27(7):1743-50
   PubMed Web of Science ®Google Scholar
• Sethi G, Sung B, Kunnumakkara AB, Aggarwal BB. Targeting TNF for Treatment of Cancer and Autoimmunity. Adv Exp Med Biol 2009;647:37-51
   PubMed Web of Science ®Google Scholar
• Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001;7(2):83-8
   PubMed Web of Science ®Google Scholar
• Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128(7):1805-11
   PubMed Web of Science ®Google Scholar
• Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012;380(9857):1909-15
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353(23):2462-76
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348(7):601-8
   PubMed Web of Science ®Google Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC Success Trial. Gastroenterology 2011;140(Suppl 1):S134
   Google Scholar
• Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007;13(16):2328-32
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60(6):780-7
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142(2):257-65; e1-3
   PubMed Web of Science ®Google Scholar
• Shealy DJ, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor-α. MAbs 2010;2(4):428-39
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, et al. A phase 2/3 randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of subcutaneous Golimumab induction therapy in patients with moderately to severely active ulcerative colitis: pursuit SC. Gut 2012;61(Suppl 3):A78
   PubMedGoogle Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295(19):2275-85
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345(15):1098-104
   PubMed Web of Science ®Google Scholar
• Wollina U, Hansel G, Koch A, et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008;9(1):1-14
   PubMed Web of Science ®Google Scholar
• Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44(12):2862-9
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138(10):807-11
   PubMed Web of Science ®Google Scholar
• Khan I, Rahman L, McKenna DB. Primary cutaneous melanoma: a complication of infliximab treatment? Clin Exp Dermatol 2009;34(4):524-6
   PubMed Web of Science ®Google Scholar
• Pozadzides JV, Pro B. Hepatosplenic T-cell lymphoma and TNF-alpha inhibitors. Expert Rev Hematol 2009;2(6):611-14
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121(5):1088-94
   PubMed Web of Science ®Google Scholar
• Arora T, Padaki R, Liu L, et al. Differences in binding and effector functions between classes of TNF antagonists. Cytokine 2009;45(2):124-31
   PubMed Web of Science ®Google Scholar
• ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50(2):206-11
   PubMed Web of Science ®Google Scholar
• Caprioli F, Bose F, Rossi RL, et al. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy. Inflamm Bowel Dis 2013;19(4):729-39
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Targan SR, Byers VS, et al. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol 2013;108(1):90-8
   PubMed Web of Science ®Google Scholar
• Camuesco D, Rodriguez-Cabezas ME, Garrido-Mesa N, et al. The intestinal anti-inflammatory effect of dersalazine sodium is related to a down-regulation in IL-17 production in experimental models of rodent colitis. Br J Pharmacol 2012;165(3):729-40
   PubMed Web of Science ®Google Scholar
• Heller F, Fuss IJ, Nieuwenhuis EE, et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002;17(5):629-38
   PubMed Web of Science ®Google Scholar
• Boirivant M, Fuss IJ, Chu A, Strober W. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 1998;188(10):1929-39
   PubMed Web of Science ®Google Scholar
• Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004;113(10):1490-7
   PubMed Web of Science ®Google Scholar
• Heller F, Fromm A, Gitter AH, et al. Epithelial apoptosis is a prominent feature of the epithelial barrier disturbance in intestinal inflammation: effect of pro-inflammatory interleukin-13 on epithelial cell function. Mucosal Immunol 2008;1(Suppl 1):S58-61
   PubMed Web of Science ®Google Scholar
• Walsh GM. Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD. Curr Opin Investig Drugs 2010;11(11):1305-12
   PubMed Web of Science ®Google Scholar
• Piper E, Brightling C, Niven R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013;41(2):330-8
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Boulet LP, Cockcroft DW, et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 2011;183(8):1007-14
   PubMed Web of Science ®Google Scholar
• AM3301 Lead Program. Available from: http://amalyte.kemin.com/rd-programs/am3301-lead-program
   Google Scholar
• Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003;52(1):65-70
   PubMed Web of Science ®Google Scholar
• Caprioli F, Pallone F, Monteleone G. Th17 immune response in IBD: a new pathogenic mechanism. J Crohns Colitis 2008;2(4):291-5
   PubMed Web of Science ®Google Scholar
• Leppkes M, Becker C, Ivanov II, et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 2009;136(1):257-67
   PubMed Web of Science ®Google Scholar
• Fitzpatrick LR, Small JS, Doblhofer R, Ammendola A. Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action. J Pharmacol Exp Ther 2012;342(3):850-60
   PubMed Web of Science ®Google Scholar
• Herrlinger KR, Diculescu M, Fellermann K, et al. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study. J Crohns Colitis 2012. Oct 15. pii: S1873-9946(12)00417-5. doi: 10.1016/j.crohns.2012.09.016. [Epub ahead of print]
   Web of Science ®Google Scholar
• Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009;9(7):480-90
   PubMed Web of Science ®Google Scholar
• Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013;38(1):13-25
   PubMed Web of Science ®Google Scholar
• Van Assche G, Sandborn WJ, Feagan BG, et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 2006;55(11):1568-74
   PubMed Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Creed TJ, et al. Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. Gastroenterology 2012;143(2):356-64; e1
   PubMed Web of Science ®Google Scholar
• Sadlack B, Merz H, Schorle H, et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75(2):253-61
   PubMed Web of Science ®Google Scholar
• Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005;201(5):723-35
   PubMed Web of Science ®Google Scholar
• Refaeli Y, Van Parijs L, London CA, et al. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 1998;8(5):615-23
   PubMed Web of Science ®Google Scholar
• O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012;36(4):542-50
   PubMed Web of Science ®Google Scholar
• Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene 2000;19(49):5662-79
   PubMed Web of Science ®Google Scholar
• Mudter J, Weigmann B, Bartsch B, et al. Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases. Am J Gastroenterol 2005;100(1):64-72
   PubMed Web of Science ®Google Scholar
• Wirtz S, Finotto S, Kanzler S, et al. Cutting edge: chronic intestinal inflammation in STAT-4 transgenic mice: characterization of disease and adoptive transfer by TNF- plus IFN-gamma-producing CD4+ T cells that respond to bacterial antigens. J Immunol 1999;162(4):1884-8
   PubMed Web of Science ®Google Scholar
• Simpson SJ, Shah S, Comiskey M, et al. T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/Signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon gamma expression by T cells. J Exp Med 1998;187(8):1225-34
   PubMed Web of Science ®Google Scholar
• West K. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Investig Drugs 2009;10(5):491-504
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367(7):616-24
   PubMed Web of Science ®Google Scholar
• Coombes JL, Maloy KJ. Control of intestinal homeostasis by regulatory T cells and dendritic cells. Semin Immunol 2007;19(2):116-26
   PubMed Web of Science ®Google Scholar
• Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Duru EA, Ameredes BT. Role of IL-10 in the resolution of airway inflammation. Curr Mol Med 2008;8(5):437-45
   PubMed Web of Science ®Google Scholar
• Huber S, Gagliani N, Esplugues E, et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3(-) and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity 2011;34(4):554-65
   PubMed Web of Science ®Google Scholar
• Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998;66(11):5224-31
   PubMed Web of Science ®Google Scholar
• Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009;361(21):2033-45
   PubMed Web of Science ®Google Scholar
• Schreiber S, Heinig T, Thiele HG, Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995;108(5):1434-44
   PubMed Web of Science ®Google Scholar
• Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000;119(6):1473-82
   PubMed Web of Science ®Google Scholar
• Steidler L, Rottiers P. Therapeutic drug delivery by genetically modified Lactococcus lactis. Ann NY Acad Sci 2006;1072:176-86
   PubMed Web of Science ®Google Scholar
• Brod SA, Marshall GD Jr, Henninger EM, et al. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Neurology 1996;46(6):1633-8
   PubMed Web of Science ®Google Scholar
• Devajyothi C, Kalvakolanu I, Babcock GT, et al. Inhibition of interferon-gamma-induced major histocompatibility complex class II gene transcription by interferon-beta and type beta 1 transforming growth factor in human astrocytoma cells. Definition of cis-element. J Biol Chem 1993;268(25):18794-800
   PubMed Web of Science ®Google Scholar
• Rudick RA, Ransohoff RM, Peppler R, et al. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996;40(4):618-27
   PubMed Web of Science ®Google Scholar
• Saksela E, Timonen T, Cantell K. Human natural killer cell activity is augmented by interferon via recruitment of ‘pre-NK' cells. Scand J Immunol 1979;10(3):257-66
   PubMed Web of Science ®Google Scholar
• Nikolaus S, Rutgeerts P, Fedorak R, et al. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut 2003;52(9):1286-90
   PubMed Web of Science ®Google Scholar
• Mannon PJ, Hornung RL, Yang Z, et al. Suppression of inflammation in ulcerative colitis by interferon-beta-1a is accompanied by inhibition of IL-13 production. Gut 2011;60(4):449-55
   PubMed Web of Science ®Google Scholar
• Kaser A, Blumberg RS. Endoplasmic reticulum stress and intestinal inflammation. Mucosal Immunol 2010;3(1):11-16
   PubMed Web of Science ®Google Scholar
• McCormick DA, Horton LW, Mee AS. Mucin depletion in inflammatory bowel disease. J Clin Pathol 1990;43(2):143-6
   PubMed Web of Science ®Google Scholar
• Pickert G, Neufert C, Leppkes M, et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 2009;206(7):1465-72
   PubMed Web of Science ®Google Scholar
• Baumann H, Wang Y, Morella KK, et al. Complex of the soluble IL-11 receptor and IL-11 acts as IL-6-type cytokine in hepatic and nonhepatic cells. J Immunol 1996;157(1):284-90
   PubMed Web of Science ®Google Scholar
• Gibson DL, Montero M, Ropeleski MJ, et al. Interleukin-11 reduces TLR4-induced colitis in TLR2-deficient mice and restores intestinal STAT3 signaling. Gastroenterology 2010;139(4):1277-88
   PubMed Web of Science ®Google Scholar
• Reinisch W, Hommes DW, Van Assche G, et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 2006;55(8):1138-44
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012;61(12):1693-700
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;135(4):1130-41
   PubMed Web of Science ®Google Scholar
• Ahern PP, Izcue A, Maloy KJ, Powrie F. The interleukin-23 axis in intestinal inflammation. Immunol Rev 2008;226:147-59
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117(2):244-79
   PubMed Web of Science ®Google Scholar
• Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111(8):1133-45
   PubMed Web of Science ®Google Scholar
• Zorzi F, Monteleone I, Sarra M, et al. Distinct profiles of effector cytokines mark the different phases of Crohn's disease. PLoS ONE 2013;8(1):e54562
   PubMed Web of Science ®Google Scholar
• Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001;108(4):601-9
   PubMed Web of Science ®Google Scholar
• Boirivant M, Pallone F, Di Giacinto C, et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology 2006;131(6):1786-98
   PubMed Web of Science ®Google Scholar
• Christophi GP, Rong R, Holtzapple PG, et al. Immune markers and differential signaling networks in ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2012;18(12):2342-56
   PubMed Web of Science ®Google Scholar